TSXV:BTI.H - Post by User
Post by
prophetoffactzon Jun 22, 2023 10:49am
304 Views
Post# 35509103
EGF assets
EGF assetsBe nice to know the milestones. This is suppose to be a Phase II ready asset so milestone payments could be near and significant. Add the potential J&J multi-product option exercise and other deals the company is still said to be pursuing and a short term liquidity issue could turn into significant incoming cash and xB3 validated by J&J in a multi-product licensing deal.
"The Company has recently signed a non-binding term sheet with Swiss Biotech Advisors (“SBA”), a group consisting of certain of the vendors of the EGF therapy platform that Bioasis acquired in June 2022 (the “EGF Assets”), for an exclusive worldwide license by Bioasis to SBA of the EGF Assets along with the right to apply the Company’s xB3 ™ platform to the EGF Assets. In return, Bioasis would receive certain milestone payments, a 5% royalty on net sales from products developed based on the licensed technology, along with a share of any sublicensing revenue generated by SBA from the licensed technology. The transaction is subject to certain conditions, including the execution of a definitive license agreement."